Kancera

The period in brief – financial summary for the first quarter 2024

• Net sales amounted to SEK 0 million (SEK 0 million)
• R&D expenses amounted to SEK 11,4 million (SEK 15,2 million)
• Operating loss for the quarter amounted to SEK –13,4 million (SEK -17,2 million)
• Loss after financial items for the quarter amounted to SEK –13,0 million (SEK -17,5 million)
• Basic and diluted earnings per share for the quarter amounted to SEK –0,13 (SEK -0,22)
• Cash flow from operating activities for the quarter amounted to SEK –14,7 million (SEK -19,0 million)
• Equity as of March 31, 2024 amounted to SEK 93,9 million (SEK 89,4 million) or SEK 0,77 (SEK 1,12) per share
• The equity ratio on 31 March 2024 was 76 percent (85 percent)
• Cash and cash equivalents on March 31, 2024 amounted to SEK 31,0 million (SEK 76,1 million)

Significant events during the first quarter 2024

• Kancera reported that the company had entered into a license agreement with the University of Newcastle, through which the company retains the exclusive rights to the results and patents from the FRACTAL study.
• Kancera reported that the company’s updated protocol for the Kandova study has been approved in Sweden, Norway and Denmark.
• Kancera reported its intention to carry out a rights issue totaling SEK 121,9 million.
• Kancera reported the outcome of the rights issue; Approximately SEK 73,0 million was raised before issue costs, which corresponded to approximately 60% of the total rights issue.

Important events after the end of the period

• Kancera has reported positive overall results from the phase I study with KAND145
• Kancera has reported that Robert Edfors has been appointed as Chief Scientific Officer and Senior Vice President Clinical Development as from September 1, 2024, and further that Maria Sahlberg has been appointed Vice President Regulatory Affairs & Compliance and Johan Schultz has been appointed Vice President Research & Development Operations.

About Kancera AB (publ)
Kancera is developing a new class of small molecule drugs targeting the fractalkine axis. Kancera’s main focus is to develop its candidate drugs for treatment of severe inflammatory diseases and cancer that currently lack effective treatments. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.

For further information
Please refer the presentation of the 2024 Q1 Interim Report, available on Kancera’s website: www.kancera.com/en/investor-relations/presentations/

or contact:
ir@kancera.com or phone: +46 (0)8-5012 60 80